CoreCap Advisors’s Pacific Biosciences PACB Stock Holding History

CoreCap Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-281	Closed	-$514	–	3254
2024 Q4	$514	Buy	+281	New	+$549	﹤0.01%	2496
2022 Q1	–	Sell	-785	Closed	-$16K	–	1602
2021 Q4	$16K	Buy	+785	New	+$18.9K	﹤0.01%	1397

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CoreCap Advisors's PACB Position: Q1 2025 in Review

CoreCap Advisors sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 281 shares — an estimated $514 sold.

CoreCap Advisors first reported a position in PACB in Q4 2021 and held it in 2 quarters. The position peaked at $16K in Q4 2021. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

CoreCap Advisors reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
CoreCap Advisors sold 281 Pacific Biosciences shares in Q1 2025, an estimated $514.
CoreCap Advisors first reported a position in Pacific Biosciences in Q4 2021 and held it in 2 quarters.
CoreCap Advisors's Pacific Biosciences position peaked at $16K in Q4 2021.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on CoreCap Advisors's 13F filing for Q1 2025, filed 9 May 2025.